Cipla has received final approval for its ANDA for darifenacin extended-release tablets, 7.5mg and 15mg, from the US FDA.
[adsense:336x280:8701650588]
Darifenacin extended-release tablets, 7.5mg and 15mg, are AB-rated generic equivalents of Allergan’s Enablex tablets, 7.5mg and 15mg, and are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. The product will be launched immediately.
[adsense:468x15:2204050025]
Enablex tablets and generic equivalents had US sales of approximately $85 million for the 12 month period ending June 2016, according to IMS Health.
Subscribe to PharmaTutor News Alerts by Email
